144 related articles for article (PubMed ID: 17649799)
1. Decision guarantee in tumour marker analysis: a cut-off independent assessment.
Bitterlich N; Schneider J
Anticancer Res; 2007; 27(4A):1933-9. PubMed ID: 17649799
[TBL] [Abstract][Full Text] [Related]
2. Cut-off-independent tumour marker evaluation using ROC approximation.
Bitterlich N; Schneider J
Anticancer Res; 2007; 27(6C):4305-10. PubMed ID: 18214036
[TBL] [Abstract][Full Text] [Related]
3. A fuzzy-classifier using a marker panel for the detection of lung cancers in asbestosis patients.
Schneider J; Bitterlich N; Kotschy-Lang N; Raab W; Woitowitz HJ
Anticancer Res; 2007; 27(4A):1869-77. PubMed ID: 17649786
[TBL] [Abstract][Full Text] [Related]
4. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
5. Centre-independent detection of non-small cell lung cancer (NSCLC) by means of classification with receiver operating characteristic (ROC)-based data transformation.
Bitterlich N; Muley T; Schneider J
Anticancer Res; 2010 May; 30(5):1661-5. PubMed ID: 20592358
[TBL] [Abstract][Full Text] [Related]
6. CYFRA 21-1 in non-small cell lung cancer--standardisation and application during diagnosis.
Pavićević R; Bubanović G; Franjević A; Stancić-Rokotov D; Samarzija M
Coll Antropol; 2008 Jun; 32(2):485-98. PubMed ID: 18756899
[TBL] [Abstract][Full Text] [Related]
7. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Philipp M; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Clin Exp Med; 2003 Feb; 2(4):185-91. PubMed ID: 12624710
[TBL] [Abstract][Full Text] [Related]
8. Detection of lung cancer in silicosis patients using a tumor-marker panel.
Schneider J
Cancer Biomark; 2010; 6(3-4):137-48. PubMed ID: 20660960
[TBL] [Abstract][Full Text] [Related]
9. Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer.
Schneider J; Bitterlich N; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Int J Clin Oncol; 2002 Jun; 7(3):145-51. PubMed ID: 12109515
[TBL] [Abstract][Full Text] [Related]
10. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
11. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
12. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma.
Zhong LP; Zhu HG; Zhang CP; Chen WT; Zhang ZY
Int J Oral Maxillofac Surg; 2007 Mar; 36(3):230-4. PubMed ID: 16965897
[TBL] [Abstract][Full Text] [Related]
13. Cut-off value determination of CYFRA 21-1 for squamous cell carcinomas of the head and neck (SCCHN).
Niemann AM; Goeroegh T; Gottschlich S; Lippert BM; Werner JA
Anticancer Res; 1997; 17(4B):2859-60. PubMed ID: 9329547
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Cyfra 21-1: a potential tumor marker for non-small cell lung carcinomas.
Karnak D; Ulubay G; Kayacan O; Beder S; Ibis E; Oflaz G
Lung; 2001; 179(1):57-65. PubMed ID: 11479694
[TBL] [Abstract][Full Text] [Related]
15. The value of CYFRA 21-1, a new tumor marker, in nasopharyngeal carcinoma.
Lin WY; Yen TC; Cheng KY; Wang SJ
Neoplasma; 1998; 45(1):21-4. PubMed ID: 9604997
[TBL] [Abstract][Full Text] [Related]
16. Improved sensitivity of fuzzy logic based tumor marker profiles for diagnosis of pancreatic carcinoma versus benign pancreatic disease.
Halm U; Rohde N; Klapdor R; Reith HB; Thiede A; Etzrodt G; Mössner J; Keller T
Anticancer Res; 2000; 20(6D):4957-60. PubMed ID: 11326646
[TBL] [Abstract][Full Text] [Related]
17. Erythrocyte and platelet phospholipid fatty acids as markers of advanced non-small cell lung cancer: comparison with serum levels of sialic acid, TPS and Cyfra 21-1.
de Castro J; Rodríguez MC; Martínez-Zorzano VS; Hernández-Hernández A; Llanillo M; Sánchez-Yagüe J
Cancer Invest; 2008 May; 26(4):407-18. PubMed ID: 18443962
[TBL] [Abstract][Full Text] [Related]
18. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
[TBL] [Abstract][Full Text] [Related]
19. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
20. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK.
Schneider J; Bitterlich N; Schulze G
Anticancer Res; 2005; 25(3A):1507-15. PubMed ID: 16033052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]